PMID- 27160311
OWN - NLM
STAT- MEDLINE
DCOM- 20161222
LR  - 20181202
IS  - 1421-9662 (Electronic)
IS  - 0001-5792 (Linking)
VI  - 136
IP  - 1
DP  - 2016
TI  - Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent 
      Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma.
PG  - 52-61
LID - 10.1159/000444624 [doi]
AB  - BACKGROUND: Diffuse large B-cell lymphomas (DLBCL) are heterogeneous diseases, 
      and the identification of additional DLBCL risk factors is especially important. 
      METHODS: In this pilot study, we determined pretreatment serum levels of vascular 
      endothelial growth factor (VEGF), osteopontin (OPN) and macrophage chemotactic 
      protein-1 (MCP-1) in 67 newly diagnosed DLBCL patients before treatment with 
      standard chemoimmunotherapy and in 30 healthy persons. RESULTS: Serum levels of 
      all three cytokines were significantly elevated in untreated patients compared to 
      controls. VEGF and OPN concentrations were higher in patients with advanced Ann 
      Arbor stage, B symptoms, Eastern Cooperative Oncology Group score >/=2, 
      International Prognostic Index (IPI) >/=3 and partial/no remission. A high MCP-1 
      level was associated with advanced stage, increased IPI and bone marrow 
      infiltration. In univariate analysis, elevated OPN and VEGF, and concurrent 
      elevation of all three biomarkers, were identified as significant predictors of 
      poor survival. Multivariate Cox analysis revealed that elevated OPN combined with 
      elevated VEGF levels was one of the best parameter subsets predicting poorest 
      survival. CONCLUSION: According to our preliminary results, serum levels of VEGF 
      and OPN before treatment predict response to therapy and survival after 
      chemoimmunotherapy, and may help to further stratify DLBCL patients into risk 
      groups.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - Duletic-Nacinovic, Antica
AU  - Duletic-Nacinovic A
AD  - Department of Hematology, University of Rijeka, Rijeka, Croatia.
FAU - Gacic, Vedrana
AU  - Gacic V
FAU - Valkovic, Toni
AU  - Valkovic T
FAU - Lucin, Ksenija
AU  - Lucin K
FAU - Fisic, Elizabeta
AU  - Fisic E
FAU - Zuvic-Butorac, Marta
AU  - Zuvic-Butorac M
FAU - Seili-Bekafigo, Irena
AU  - Seili-Bekafigo I
FAU - Jonjic, Nives
AU  - Jonjic N
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20160510
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 106441-73-0 (Osteopontin)
SB  - IM
CON - Mol Pathol. 1998 Oct;51(5):273-6. PMID: 10193522
CON - Cancer Res. 2008 Jan 1;68(1):152-61. PMID: 18172307
CON - Folia Histochem Cytobiol. 2011;49(2):240-7. PMID: 21744323
CON - Eur J Haematol. 2012 Nov;89(5):395-402. PMID: 22882209
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/diagnosis
MH  - *Osteopontin
MH  - Pilot Projects
MH  - Prognosis
MH  - Vascular Endothelial Growth Factor A/*blood
EDAT- 2016/05/11 06:00
MHDA- 2016/12/23 06:00
CRDT- 2016/05/11 06:00
PHST- 2015/02/09 00:00 [received]
PHST- 2016/02/10 00:00 [accepted]
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2016/12/23 06:00 [medline]
AID - 000444624 [pii]
AID - 10.1159/000444624 [doi]
PST - ppublish
SO  - Acta Haematol. 2016;136(1):52-61. doi: 10.1159/000444624. Epub 2016 May 10.